Pan D, Li TP, Xiong JH, Wang SB, Chen YX, Li JF, Xiao Q. Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review. World J Clin Cases 2022; 10(9): 2818-2828 [PMID: 35434106 DOI: 10.12998/wjcc.v10.i9.2818]
Corresponding Author of This Article
Qi Xiao, PhD, Chief Doctor, Department of General Surgery, The First Affiliated Hospital of Nanchang University, No.17 Yongwai Zheng Road, Donghu District, Nanchang 330006, Jiangxi Province, China. xiaoqidoctor@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Mar 26, 2022; 10(9): 2818-2828 Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2818
Treatment with sorafenib plus camrelizumab after splenectomy for primary splenic angiosarcoma with liver metastasis: A case report and literature review
Dan Pan, Tai-Ping Li, Jian-Hui Xiong, Jian-Feng Li, Qi Xiao, Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
Shu-Bo Wang, Yao-Xu Chen, The Medical Department, 3D Medicines Inc., Shanghai 201114, Shanghai Province, China
Author contributions: Xiao Q was the physician in charge, confirmed the diagnosis and contributed the details on the histologic diagnosis; Pan D contributed to the case report design and manuscript drafting, and provided the histologic image; Wang SB and Chen YX were responsible for NGS testing; Li TP and Xiong JH reviewed the manuscript; Xiao Q and Li JF were the principal authors of the paper, had full access to all data, and are the guarantors; and all authors read and confirmed the final version of this article.
Supported bythe Natural Science Foundation of Jiangxi Province (No. 20192BAB215012 and No. 20212BAB206027), the Health Commission of Jiangxi Province (No. 20203206).
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
Conflict-of-interest statement: There is no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qi Xiao, PhD, Chief Doctor, Department of General Surgery, The First Affiliated Hospital of Nanchang University, No.17 Yongwai Zheng Road, Donghu District, Nanchang 330006, Jiangxi Province, China. xiaoqidoctor@163.com
Received: August 9, 2021 Peer-review started: August 9, 2021 First decision: November 16, 2021 Revised: December 4, 2021 Accepted: February 19, 2022 Article in press: February 19, 2022 Published online: March 26, 2022 Processing time: 225 Days and 9.2 Hours
Abstract
BACKGROUND
Primary splenic angiosarcoma (PSA) is an extremely rare and aggressive mesenchymal malignancy with high metastatic potential and a poor prognosis. There are no established treatment guidelines for PSA, even for adjuvant therapy. This rare case may provide a reliable therapeutic regime for a better prognosis.
CASE SUMMARY
A 49-year-old female who complained of right-upper quadrant abdominal pain was diagnosed as having PSA with splenic rupture and liver metastasis. After splenectomy and liver tumor resection, she received sorafenib and camrelizumab therapy. After 15 mo of follow-up, she is in good condition, without recurrence or any identified metastasis.
CONCLUSION
Immunotherapy combined with targeted therapy could be a potential option for the adjuvant therapy of PSA.
Core Tip: Splenectomy is the preferred treatment for primary splenic angiosarcoma (PSA); however, PSA patients may experience a good or poor prognosis after splenectomy. Although the prognosis in patients with liver metastases or rupture of the spleen is extremely poor, immunotherapy or targeted therapy has not been attempted after surgery. This case is the first report of a PSA patient with liver metastasis and splenic rupture, receiving sorafenib plus camrelizumab as adjuvant therapy. After 15 mo of follow-up, the patient is in good condition without recurrence or identified metastasis. Apart from chemotherapy and radiotherapy, targeted therapies and immunotherapy may also be an option for adjuvant therapy.
